Nurix Therapeutics Announces Initial Clinical Signs of Brain Activity for NX-5948, an Orally Administered Compound That Crosses Blood-Brain Barrier and Targets BTK for Treating B Cell Cancers.

The article presents the clinical trial outcomes that failed globally in February.

Foghorn Therapeutics Unveils Novel Early-Stage Research Findings for Unique BRM Targeted Inhibitor FHD-909 and Distinct CBP & EP300 Degrader Initiatives in Cancer Treatment.

Fusion Pharmaceuticals Reveals Preliminary Results of Phase 2 TATCIST Study on FPI-2265 During AACR 2024 Convention.

Innate Pharma Showcases Pre-IND Candidate IPH45's Preclinical Results at AACR 2024 - A New Antibody-Drug Conjugate Targeting Nectin-4.

Synthekine Unveils Encouraging Early Outcomes from Early-stage Clinical Study of Altered IL-2 Agent, STK-012, Aimed at Advanced Solid Cancer Therapy.

Obsidian Therapeutics Reveals Encouraging Safety and Effectiveness Results After 25 Weeks of Monitoring in Initial Human Trials for OBX-115.

CytomX Therapeutics has revealed initial treatment using CX-2051, a selective EpCAM-targeted antibody-drug conjugate, in an early-stage trial involving individuals with progressive solid malignancies.

April 12th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

CHS-1000, an Innovative ILT4 Antagonist Antibody, Showcased Through Early-Stage Research at AACR's 2024 Gathering.

Vivet Therapeutics Administers Initial Dose to First Participant in Second Group of Phase 1/2 GATEWAY Study for Wilson Disease Therapy.

Up to now, at the AACR meeting, updates on the clinical progress of several ADC drugs have been presented, involving targets such as HER2, BCMA, CD123, FRα, CCR7, Axl, etc.